ClinicalQuiz: So You Think You’re a Hepatitis C Expert
Hello folks,
Back in July
Clinical Care Options released
part one of a three part online quiz containing 35 questions on hepatitis C, answered by nine world-renowned hepatology experts. Today CCO released part two, links and a description are provided below with a sample question from the second part of "
So You Think You’re a Hepatitis C Expert." For more details of the quiz itself, please visit
clinicaloptions.com/HCVquiz.
*Free registration is required
Part One
Now participants can answer
part one of the hepatitis C case-based questions on an
iPad*,
iPhone* and
Android or online-by
clicking here .
* To install this app, please visit this page using your
iPhone or iPad's Web browser.
ClinicalQuiz: Part 1 - So You Think You’re a Hepatitis C Expert, Educational Material
Explore a collection of clinical pearls on HCV management in this series of case
scenarios from 11 leading international experts on hepatitis C.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify best practices for the treatment of hepatitis C with approved
agents including boceprevir, telaprevir, peginterferon, and ribavirin
- Assess and monitor the individualized care of patients receiving HCV therapy
to address adverse events, adherence, and other issues
- Evaluate the impact of emerging data on investigational HCV agents for the
management of patients with hepatitis C today and in the future
- Assess and identify potential drug-drug interactions prior to the initiation
of HCV protease inhibitor-based therapy
Part Two
This CME-certified activity provides clinical management
insights from leading experts on the care of patients with hepatitis C.
Below is one example of the 32 questions found in the quiz:
Patient Case: Retreatment of a Null Responder With Telaprevir
The
patient is a 47-year-old woman with genotype 1 HCV infection. She was previously
treated 2 years ago with peginterferon and ribavirin and experienced a null
response but treatment was well tolerated. She has a close friend who died from
HCV-related liver disease and thus is very motivated to receive retreatment in
hopes of clearing the virus. A current liver biopsy reveals stage 2 fibrosis. At
current baseline, her HCV RNA level is 2.5 x 10
6 IU/mL. The patient
begins telaprevir-based therapy with 12 weeks of triple therapy with telaprevir
plus peginterferon/ribavirin. After 4 weeks, her HCV RNA level is undetectable
and it remains so at Week 12.
What course of therapy should you follow for this patient, assuming no
futility rules are breached?
Analysis by Paul J. Pockros, MD:This patient should continue
peginterferon/ribavirin therapy through Week 48. According to the prescribing
information, all previous null responders, regardless of on-treatment response
pattern, should receive a regimen consisting of 12 weeks of
peginterferon/ribavirin plus telaprevir therapy followed by 36 weeks of dual
peginterferon/ribavirin.
[3] Had she been treatment naive or a
previous relapser, this on-treatment response would enable her to stop therapy
at Week 24. Had she been a previous partial responder with this response, her
course would have been the same as null responders and she would have needed 48
total weeks of treatment.....
Other Questions...
Patient Case: Management of Rash in a Patient Receiving Telaprevir
Patient Case: Management of Hair Loss During Boceprevir Therapy
Case: Management of Anorectal Symptoms in a Patient Receiving Telaprevir
Patient Case: Management of HCV in an Elderly Man..............
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify best practices for the treatment of hepatitis C with approved
agents including boceprevir, telaprevir, peginterferon, and ribavirin
- Assess and monitor the individualized care of patients receiving HCV therapy
to address adverse events, adherence, and other issues
- Evaluate the impact of emerging data on investigational HCV agents for the
management of patients with hepatitis C today and in the future
- Assess and identify potential drug–drug interactions prior to the initiation
of HCV protease inhibitor–based therapy
No comments:
Post a Comment